

Special Issue

Human Papillomavirus Vaccine Against Cervical Cancer: New Usage Strategies and Coverage Issues

Message from the Guest Editors

Cervical cancer (CC) represents one of the most common female cancers worldwide, with 80% of cases originating from developing countries. These data are surprising given that CC is the only tumor that has primary and secondary prevention. The WHO has set goals for its elimination by 2030, proposing a vaccination coverage of 90%. In many countries worldwide, the vaccination coverage is well below this set goal. Hence, there is a need to implement vaccination coverage. This Special Issue aims to provide evidence regarding the use of the HPV vaccine in different settings. Adolescent girls represent the primary target, but its use after excisional or definitive treatments is a trending topic of interest. Furthermore, the tools necessary for its implementation aimed at women of screening age or parents with daughters of vaccination age are topics of crucial interest.

Guest Editors

Dr. Luca Giannella

Gynecologic Section, Department of Odontostomatologic and Specialized Clinical Sciences, Università Politecnica delle Marche, 60213 Ancona, Italy

Dr. Andrea Ciavattini

Gynecologic Section, Department of Odontostomatologic and Specialized Clinical Sciences, Università Politecnica delle Marche, 60213 Ancona, Italy

Deadline for manuscript submissions

30 April 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/195957

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).